Arginine vasopressin (AVP) is a cyclic nonapeptide hormone secreted from the posterior pituitary gland. AVP has a variety of physiological functions, such as regulation of blood pressure, secretion of ACTH and control of water in the kidney. These physiological functions are regulated through three receptors (V 1A , V 1B and V 2 ). Among these receptors, the V 1A receptor mediates the vasoconstrictive action of AVP. The receptor is found in vascular smooth muscle, the liver, platelets, and renal mesangial cells. [1] [2] [3] [4] Due to the physiological properties of AVP and the distribution of the V 1A receptor, abnormal secretion of AVP causes high blood pressure, cardiac disease, and kidney disease through the V 1A receptor. 5) Therefore, V 1A receptor antagonists are expected to be important new curative drugs for these diseases. OPC-21268 (1) and SR49059 (2) have been reported as non-peptide V 1A receptor antagonists, 6,7) and we have discovered and reported the 4,4-difluoro-5-methylidene-2,3,4,5-tetrahydro-1H-1-benzazepine derivatives as V 1A receptor antagonists, and introduced a 2-ethoxybenzoyl group into these derivatives (3, 4) ( Fig. 1 ).
Due to the physiological properties of AVP and the distribution of the V 1A receptor, abnormal secretion of AVP causes high blood pressure, cardiac disease, and kidney disease through the V 1A receptor. 5) Therefore, V 1A receptor antagonists are expected to be important new curative drugs for these diseases. OPC-21268 (1) and SR49059 (2) have been reported as non-peptide V 1A receptor antagonists, 6, 7) and we have discovered and reported the 4,4-difluoro-5-methylidene-2,3,4,5-tetrahydro-1H-1-benzazepine derivatives as V 1A receptor antagonists, and introduced a 2-ethoxybenzoyl group into these derivatives (3, 4) (Fig. 1 ). 8) In preceding papers, 9, 10) we reported the discovery of two AVP dual antagonists (YM087 (conivaptan), 5; and YM-35471, 6) which possess strong binding affinities for both V 1A and V 2 receptors, through optimization of the benzazepine moiety (shown in box A) of compound 7 (Fig. 2 ).
11)
The introduction of various groups in the 2-phenyl position (shown in box B) of compound 7 resulted in changes in selectivity between the V 1A and V 2 receptors. That is to say, the replacement of B with either 2-(4-NHAc)Ph or 2-(4-OMe)Ph resulted in V 1A receptor selectivity versus the V 2 receptor. On the other hand, replacement of B by 2-(3-Me)Ph, 2-(4-Et)Ph, 2-(4-NH 2 )Ph or 2-(4-OH)Ph gave V 2 selectivity. For all these compounds, selectivity between the two receptors was insufficient, but we concluded that the R 2 group plays an important role in changing receptor selectivity. Therefore, we tried to convert the 2-phenyl group into other aryl groups, such as azole groups (8a-g). The most effective compound with an azole group introduced into the skeleton of (Z)-4Ј-{[(4,4-difluoro-5-carbamoylmethylene-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl}-benzanilide underwent further optimization of the R 3 group (9a-k), and this led to a series of compounds pos- sessing highly potent affinity and selectivity for the V 1A receptor. Here, we describe the synthesis, structure-activity relationships, and pharmacological properties of these novel compounds.
Preparation of Highly Potent and Selective Non-Peptide Antagonists of the Arginine Vasopressin V 1A Receptor by Introduction of a 2-Ethyl-1H-1-imidazolyl Group

Chemistry
The synthetic pathways of the compounds listed in Tables  1-3 are shown in Charts 1-3. Intermediates of 2,3,4,5-tetrahydro-1H-1-benzazepine derivatives (11a-f, 12) were synthesized as outlined in Chart 1. The 2-(2-substituted-1H-imidazol-1-yl) or 2-(1H-1,2,4-triazol-1-yl) benzoic acid derivatives (11a-f) were obtained by condensation of 2-fluorobenzonitrile (10) and 2-substituted imidazole or a triazole, 12) followed by hydrolysis of the nitrile group under basic conditions. The methyl 2-cyanobenzoate (12) was synthesized as described below. The phthalic anhydride (13) was hydrolyzed by 28% NH 4 OH to give 2-(aminocarbonyl)benzoic acid (14) , 13) and compound 12 was obtained by treatment of 14 with methyl chloroformate.
14)
The 2,3,4,5-tetrahydro-1H-1-benzazepine derivatives (8a-g) were synthesized according to the route shown in Chart 2. The imidazole and triazole derivatives (8a-f) were prepared by condensation of 1-(4-aminobenzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepine (15) 11) and 11a-f in the presence of 1-ethyl-3-(dimethylaminopropyl) carbodiimide hydrochloride (WSC · HCl). Compound 12 was hydrolyzed with 1 M NaOH to give the corresponding carboxylic acid derivative, followed by the addition of oxalyl chloride to give the acyl chloride derivative. This acyl chloride was condensed with 15 to give the 2-cyanobenzanilide derivative 16. The tetrazole derivative (8g) was synthesized by treating 16 with nBu 3 SnN 3 . 15, 16) The 4,4-difluoro-5-methylidene-2,3,4,5-tetrahydro-1H-1-benzazepine derivatives (9a-k) were prepared according to the methods shown in Chart 3. The methyl ester derivative 18 was obtained by acylation of 17 10) with the acyl chloride derivative of 11c. Hydrolysis of the methyl ester in 18 with 1 M NaOH afforded the acetic acid derivative 19. The target compounds (9a-k) were synthesized by condensation of 19 and various amines in the presence of WSC · HCl and 1-hydroxybenzotriazole (HOBt).
Results and Discussion
Binding Affinities Methods for determining the in vitro AVP receptor binding affinities have been described in a previous paper.
8) The results of binding assay of the compounds are shown in Tables 1-3 . Initially, we investigated the role of the R 2 position in V 1A selectivity in 2,3,4,5-tetrahydro-1H-1-benzazepine derivatives, as shown in Table 1 . When the 1H-imidazol-1-yl group (8a) was introduced at the R 2 position, selectivity for the V 1A receptor versus the V 2 receptor was greater than that of 7. Additionally, the 1H-1,2,4-triazol-1-yl (8f) and 1H-tetrazol-1-yl (8g) derivatives showed slight V 1A selectivity, but the V 1A binding affinity of these derivatives (8f, g) decreased compared to 7. It was concluded that the nitrogen atom of the azole group contributed to the increase in V 1A receptor selectivity.
Among compounds 8a, 8f and 8g, the imidazole derivative (8a) tended to possess higher V 1A binding affinity and selectivity than 8f or 8g, and the imidazolyl moiety was therefore studied further. The methyl (8b) and ethyl (8c) derivatives at the 2-position of imidazole (R 4 ) exhibited highly potent binding affinity and selectivity for the V 1A receptor, but the introduction of a bulky substituent such as an n-propyl or phenyl group (8d, e) decreased the affinity and selectivity. Consequently, the introduction of a 2-ethyl-1H-imidazol-1-yl group was effective in increasing V 1A receptor selectivity versus the V 2 receptor, while maintaining the V 1A binding affinity. These observations suggested that V 1A binding affinity and selectivity were influenced by both the electronic effect of the azole group and the steric effect of the substituent at the R 4 position. Based on these results, we tried to convert the 2-phenyl group of compound 6 (YM-35471 skeleton) into a 2-ethyl-1H-imidazol-1-yl group, and further modifications of various amide groups at the R 3 position were performed. Because the YM-35471 skeleton possesses high binding affinities for the V 1A and V 2 receptors, we thought that introduction of a 2-ethyl-1H-imidazol-1-yl group might give compounds with both highly potent binding affinity and selectiv- ity for the V 1A receptor. The binding affinities of 4,4-difluoro-5-methylidene-2,3,4,5-tetrahydro-1H-1-benzazepine derivatives are shown in Table 2 . All these derivatives (9a-k) showed an increase in V 1A receptor selectivity versus the V 2 receptor, compared to 6 and 8c, and exhibited more potent binding affinity for the V 1A receptor, compared to 8c. The alkyl-substituted derivatives (9b-i) possessed highly potent binding affinity compared with the carbamoyl derivative 9a, but the introduction of a bulky substituent group, such as in compounds 9h and 9i, was found to decrease selectivity for the V 1A receptor. The cyclopropyl-substituted derivative (9f) exhibited the most potent affinity among these derivatives and showed a 457-fold selectivity for the V 1A versus the V 2 receptor. In the derivatives containing oxygen atoms (9j, k), the V 1A selectivity of 9j was insufficient, but compound 9k showed a more potent affinity for the V 1A receptor, compared with corresponding hydrocarbon derivative (9i). Therefore, the influence of the oxygen atom in V 1A selectivity was unclear. These results suggested that V 1A binding affinity and selectivity are influenced by a steric effect at the R 3 position, making substitution with a cyclopropyl group suitable for obtaining the desired compound.
Subsequently, we investigated the binding affinities of compound 9f for cloned human V 1A (hV 1A ) and V 2 (hV 2 ) receptors (Table 3) . 8) Compound 9f exhibited potent binding affinity for the V 1A receptor and 140-fold selectivity for the V 1A versus the V 2 receptor. Additionally, 9f showed 70-fold V 1A selectivity compared to 6. Therefore, conversion of the 2-phenyl group into a 2-ethyl-1H-imidazol-1-yl group also contributed to increased V 1A selectivity in cloned human AVP receptors.
Antagonist Activity The V 1A receptor antagonist activity was determined by measuring inhibition of the AVP-induced diastolic blood pressure (DBP) response in pithed rats after intravenous (i.v.) administration. The dose of the compound causing a 50% inhibition of the pressor response to AVP (ID 50 ) was calculated. The experimental method used to determine AVP antagonist activity has been described in a previous paper. 8) Compound 9f was selected and the above in vivo experiment was performed. Results showed that 9f exhibited potent antagonist activity (ID 50 : 0.0010 mg/kg i.v.) for the V 1A receptor. Furthermore, the antagonist activity of 9f was more effective than that of 6 (ID 50 : 0.0027 mg/kg i.v.). Therefore, introduction of a 2-ethyl-1H-imidazol-1-yl group at the R 2 position and a cyclopropylamino group at the R 4 position provided the most potent V 1A receptor antagonist activity.
Conclusion
In this paper, we have described the synthesis of 2-substituted 4Ј-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl] benzanilide derivatives and (Z)-2-substituted 4Ј-[(4,4-difluoro-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]benzanilide derivatives, and evaluated their AVP receptor binding affinities and antagonist activities. It was found that the introduction of a 2-ethyl-1H-imidazol-1-yl group at the 2-position increased V 1A selectivity versus the V 2 receptor. In C-NMR spectra were obtained on a JNM-400 spectrometer. The chemical shifts are expressed in d (ppm) values with tetramethylsilane as an internal standard. Abbreviations of 1 H-NMR signal patterns are as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad peak. Mass spectra were obtained using a JEOL JMS-DX300 spectrometer. Elemental analysis was performed with a Yanaco MT-5. Melting points were determined on a Yanaco MP-500D micro melting point apparatus without correction. Column chromatography on silica gel was performed using Merck KGaA Silica gel 60 (0.040-0.063 mm).
General Procedure for Synthesis of 2-Substituted Benzoic Acid Derivatives (11a-f) 12) A mixture of 2-fluorocyanobenzene (10, 5.00 g, 41.3 mmol), imidazole derivatives or 1H-1,2,4-triazole (41.3 mmol) and K 2 CO 3 (6.39 g, 45.4 mmol) in dimethyl sulfoxide (DMSO, 25 ml) was stirred at 100°C for 3 h. After cooling, the reaction mixture was poured into H 2 O (50 ml) and the product was precipitated readily and separated out. The precipitate was washed with H 2 O (50 mlϫ2) and dried to give 2-substituted cyanobenzene derivatives. Then, these derivatives were hydrolyzed with KOH (14.5 g, 258 mmol), H 2 O (3.0 ml), and 2-ethoxyethanol (30 ml). After refluxing for 3 h, the reaction mixture was diluted with H 2 O and acidified with 12 M HCl (20 ml) under cooling at 0°C. The mixture was extracted with CHCl 3 (50 mlϫ2). The organic layer was concentrated in vacuo and the residual solvent was separated as the ethanol (EtOH) azeotrope. The residue was diluted with brine and extracted with CHCl 3 (50 mlϫ2). The organic extract was dried over anhydrous MgSO 4 and concentrated in vacuo. The 2-substituted benzoic acid derivatives (11a-f) were obtained as a colorless crystal by recrystallization from 2-propanol-methanol (MeOH). All physical and spectral data for the 2-substituted benzoic acid derivatives are shown in Table 4 .
Phthalamic Acid (14) 13) A suspension of phthalic anhydride (13, 10.0 g, 67.5 mmol) in 28% NH 4 OH (50 ml) was stirred at 70°C for 10 min, and the reagent was dissolved. After cooling to 0°C, the product precipitated readily and was separated out. To the filtrate, tetrahydrofuran (THF, 50 ml) was added and the precipitate was obtained again. The combined precipitates were dissolved in H 2 O (25 ml) and a reprecipitation was performed with the addition of 12 M HCl (10 ml, dropwise) while cooling. The precipitate was filtered and dried. The compound 14 (4.69 g, 28.4 mmol, 42%) was obtained as a colorless crystal. To a stirred suspension of compound 14 (3.52 g, 21.3 mmol) in CH 2 Cl 2 (50 ml) at 0°C were added triethylamine (Et 3 N; 6.23 ml, 44.7 mmol) and methyl chloroformate (3.62 ml, 46.8 mmol). After stirring at room temperature for 8 h, the reaction mixture was extracted with CHCl 3 , washed with H 2 O, dried over anhydrous MgSO 4 , and concentrated in vacuo. The product was washed with hexane and dried. The title compound 12 (3.34 g, 20.7 mmol, 97% yield) was obtained as a colorless crystal. Imidazol-1-yl)-4Ј-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl) carbonyl]benzanilide Monohydrochloride (8a) To a cooled mixture of 11a (170 mg, 0.90 mmol) in CH 2 Cl 2 (3 ml) and N-methylmorpholine (0.12 ml) was added 1-ethyl-3-(dimethylaminopropyl)carbodiimide hydrochloride (WSC · HCl; 190 mg, 0.90 mmol). After the mixture was stirred for 1 h, a solution of 15 11) (200 mg, 0.751 mmol) in CH 2 Cl 2 (3 ml) was added. The whole mixture was stirred at room temperature overnight. To the mixture was added a saturated aqueous solution of NaHCO 3 , and it was extracted with CHCl 3 . The organic layer was dried over anhydrous MgSO 4 and concentrated in vacuo. The crude product was purified by column chromatography (eluent, CHCl 3 : MeOHϭ19 : 1), yielding 286 mg (0.655 mmol, 87% yield) of 8a as a free amine. The resulting amine (236 mg, 0.602 mmol) was diluted with ethyl acetate (AcOEt; 10 ml), and the solution was cooled at 0°C. To this solution, 4 M solution of HCl in AcOEt (4 M HCl/AcOEt; 10 ml) was added. The mixture was subsequently concentrated in vacuo and recrystallized from MeOH-diethyl ether (Et 2 O) to give 200 mg (0.422 mmol, 56% from 11a) of 8a as a colorless amorphous substance. The compounds 8b-f were prepared from 15 and 11b-f in the same manner as described in the synthesis of 8a.
2-(1H-
2-(2-Methyl-1H-imidazol-1-yl)-4Ј-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]benzanilide Monohydrochloride (8b)
Colorless amorphous substance. Yield: 71%. -1H-imidazol-1-yl)-4Ј-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl) -1H-imidazol-1-yl)-4Ј-(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl) 2-(1H-1,2,4-Triazol-1-yl)-4Ј-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1 4Ј-[(2,3,4,5-Tetrahydro-1H-1-benzazepin-1-yl) carbonyl]-2-cyanobenzanilide (16) The mixture of compound 12 (3.29 g, 20.4 mmol), MeOH (60 ml) and 1 M NaOH (22 ml) were stirred at room temperature for 8 h, and then concentrated in vacuo. The residue was diluted with H 2 O and CHCl 3 , and then acidified with 1 M HCl (22 ml) under cooling. The resulting precipitate was collected, washed with H 2 O and hexane, and dried in vacuo. The corresponding benzoic acid derivative (2.21 g, 15.0 mmol, 74%) was obtained as a colorless crystal. The benzoic acid derivatives (663 mg, 4.51 mmol) and a drop of N,N-dimethylformamide (DMF) in CH 2 Cl 2 (30 ml) was added oxalyl chloride (0.59 ml, 6.76 mmol). The mixture was stirred at room temperature for 2 h and concentrated in vacuo to give colorless oil. To an ice-cooled mixture of 15 11) (1.00 g, 3.76 mmol), pyridine (20 ml) and a catalytic amount of 4-dimethylaminopyridine (DMAP) was added a solution of above colorless oil in CH 2 Cl 2 (20 ml). The mixture was stirred at room temperature for 8 h, and then concentrated in vacuo. The residue was diluted with CHCl 3 , and the organic layer was washed with 1 M NaOH, 1 M HCl, and brine, dried over anhydrous MgSO 4 and concentrated in vacuo. The crude product was purified by column chromatography on silica gel (eluent, CHCl 3 /AcOEtϭ20/1) and recrystallized from CHCl 3 -Et 2 O to give 932 mg of 16 (2.36 mmol, 63%) as a yellow crystal. To an ice-cooled mixture of 2-(2-ethyl-1H-imidazol-1-yl)benzoic acid (11c, 3.00 g, 13.9 mmol) and a drop of DMF in CH 2 Cl 2 (60 ml) was added oxalyl chloride (1.82 ml, 20.9 mmol). The mixture was stirred at room temperature for 3 h, diluted with CHCl 3 , and concentrated in vacuo to give a colorless powder. The colorless powder (acyl chloride derivatives) was used after the reaction without further purification. To an ice-cooled mixture of methyl (Z)-[1-(4-aminobenzoyl)-4,4-difluoro-2,3,4,5-tetrahydro-1H-1-benzazepin-5-ylidene]acetate (17) 10) (4.31 g, 11.6 mmol) and Et 3 N (1.94 ml) in CH 2 Cl 2 (40 ml) was added a solution of this colorless powder in CH 2 Cl 2 (30 ml). The mixture was stirred at room temperature for 8 h, and then concentrated in vacuo. The residue was diluted with chloroform and the organic layer was washed with saturated aqueous solution of Na 2 CO 3 , 1 M HCl and brine, dried over anhydrous MgSO 4 , and concentrated in vacuo. The crude product was chromatographed on a silica gel column using CHCl 3 08 (1H, s), 7.17 (1H, t, Jϭ8 Hz), 7.29 (1H, t, Jϭ8 Hz) 1H-1-benzazepin-1-yl}carbonyl)-2-(2-ethyl-1H-1-imidazol-1-yl) benzanilide Monohydrochloride (9e) The free amine of 9e was dissolved in 2-propanol (10 ml), and to this ice-cooled solution was added 4 M HCl/AcOEt (0.2 ml). After removing the volatiles, the residue was recrystalized from CH 3 CN and dried to give 9e (89%) as a colorless powder. mp 182-184°C. 
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